Clinical characteristics of patients with secondary AML
| UPN . | Sex . | Age, y . | MDS FAB . | Time to AML, days . | % BM blast . | Cytogenetics . |
|---|---|---|---|---|---|---|
| 461282 | M | 70 | RAEB | 1751 | 69 | 45,XY,del(5)(q22q33),-17, del(20)(q11.2)[14]/46,XY[4] |
| 667720 | F | 67 | RAEB | 644 | Not done | 46,XX[19]/45,XX,-7[1] |
| 859640 | F | 64 | RA | 252 | 25 | 47,XX,+13[3]/46,XX[17] |
| 610184 | F | 46 | RA | 314 | 38 | 41-44,XX,add(1)(p36.3),del(5)(q13q33),-7,-13,dic(16;21)(p13.3;p11.2),add(17)(p13), −18, −22, +mar[cp17]/84,idemx2[cp2]/44,XX,-17, −22[1] |
| 182896 | M | 77 | RA | 1047 | 51 | 47,XY,add(4)(p16),del(5)(q15q33), −7,+8,del(9)(q22),+22,+2mar[1]/54,XY,+3,+8,+8,+9,-12,+15,+19,+20,-21,+22,+2-3mar[cp11]/46,XY[8] |
| 266395 | M | 64 | RAEB | 75 | 66 | 46,XY[17] |
| 288033 | F | 30 | RAEB | 28 | 43 | 46,XX[20] |
| 298273 | M | 26 | RAEB-T | 131 | 35 | 46,XY[20] |
| 689147 | F | 69 | RAEB | 421 | Not done | 48,XX,+1,del(5)(q15;q33),+11,i(22)(q10)[20] |
| 891669 | M | 66 | RA | 323 | 75 | 46,XY,inv(3)(q21q26.2)[20] |
| 169510 | M | 58 | RAEB | 796 | 28 | 46,XY[20] |
| 989382 | M | 69 | RA | 1332 | 89 | Unknown |
| 178647 | M | 61 | RA | 368 | 23 | 46,XY[20] |
| 759134 | M | 67 | RA | 400 | 21 | 46,XY[20] |
| 838538 | M | 67 | RAEB | 437 | 51 | 40∼46,XY,add(X)(p22.1),-2,del(5)(q22q35), del(7)(q22),+8,-12,-16,+mar[19]/46,XY[1] |
| UPN . | Sex . | Age, y . | MDS FAB . | Time to AML, days . | % BM blast . | Cytogenetics . |
|---|---|---|---|---|---|---|
| 461282 | M | 70 | RAEB | 1751 | 69 | 45,XY,del(5)(q22q33),-17, del(20)(q11.2)[14]/46,XY[4] |
| 667720 | F | 67 | RAEB | 644 | Not done | 46,XX[19]/45,XX,-7[1] |
| 859640 | F | 64 | RA | 252 | 25 | 47,XX,+13[3]/46,XX[17] |
| 610184 | F | 46 | RA | 314 | 38 | 41-44,XX,add(1)(p36.3),del(5)(q13q33),-7,-13,dic(16;21)(p13.3;p11.2),add(17)(p13), −18, −22, +mar[cp17]/84,idemx2[cp2]/44,XX,-17, −22[1] |
| 182896 | M | 77 | RA | 1047 | 51 | 47,XY,add(4)(p16),del(5)(q15q33), −7,+8,del(9)(q22),+22,+2mar[1]/54,XY,+3,+8,+8,+9,-12,+15,+19,+20,-21,+22,+2-3mar[cp11]/46,XY[8] |
| 266395 | M | 64 | RAEB | 75 | 66 | 46,XY[17] |
| 288033 | F | 30 | RAEB | 28 | 43 | 46,XX[20] |
| 298273 | M | 26 | RAEB-T | 131 | 35 | 46,XY[20] |
| 689147 | F | 69 | RAEB | 421 | Not done | 48,XX,+1,del(5)(q15;q33),+11,i(22)(q10)[20] |
| 891669 | M | 66 | RA | 323 | 75 | 46,XY,inv(3)(q21q26.2)[20] |
| 169510 | M | 58 | RAEB | 796 | 28 | 46,XY[20] |
| 989382 | M | 69 | RA | 1332 | 89 | Unknown |
| 178647 | M | 61 | RA | 368 | 23 | 46,XY[20] |
| 759134 | M | 67 | RA | 400 | 21 | 46,XY[20] |
| 838538 | M | 67 | RAEB | 437 | 51 | 40∼46,XY,add(X)(p22.1),-2,del(5)(q22q35), del(7)(q22),+8,-12,-16,+mar[19]/46,XY[1] |
FAB, French-American-British; MDS, myelodysplastic syndrome; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RAEB-T, refractory anemia with excess blasts in transformation.